Biotech Values

[DewDiligence]

DRNA +12% on NASH collaboration with B-I:

https://finance.yahoo.com/news/boehringer-ingelheim-dicerna-announce-collaboration-103000619.html

Boehringer Ingelheim and Dicerna Pharmaceuticals (DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreement to discover and develop novel GalXC RNAi therapeutics for the treatment of chronic liver diseases. The partnership will initially focus on nonalcoholic steatohepatitis (NASH)…

…Under the terms of the agreement, Dicerna may receive more than $200 million from Boehringer Ingelheim, including an upfront payment, development and commercial milestone payments, and research and development reimbursement for a GalXC candidate product addressing an undisclosed NASH target. Dicerna is also eligible to receive royalties staggered up to double-digits on worldwide net sales.

According to sources on Twitter, the up-front amount is only $10M.